Relypsa Inc (RLYP) 33.98 $RLYP
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Wed Feb 04, 7:30AM CST
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 2, 2015, the compensation committee of the company's board of directors granted nine new employees an option to purchase an aggregate of 41,400 shares of the company's common stock with a per share exercise price of $32.73, the closing trading price on the grant date. The stock options were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5653(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 33.98 (+0.60)
Relypsa to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 17 Annual BIO CEO & Investor Conference on February 10, 2015 at 9:00 a.m. ET.
RLYP: 33.98 (+0.60)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 46.77 (+3.42), RLYP: 33.98 (+0.60)
Relypsa Announces Helen Torley, M.B. Ch.B., M.R.C.P. Joins Board of Directors
GlobeNewswire - Thu Jan 22, 3:30PM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches.
RLYP: 33.98 (+0.60)
Relypsa: Unglamorous Niche, Exciting Opportunity
Investing Doc - at Seeking Alpha - Tue Jan 20, 12:28PM CST
RLYP: 33.98 (+0.60)
Cramer's Mad Money: Cramer's Game Plan (1/16/15)
SA Editor Michael Hopkins - at Seeking Alpha - Sun Jan 18, 12:06AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 16. After a few big drubbings, stocks caught a break Friday, thanks to a rally in oil and a strong consumer confidence number, data Cramer said is...
GD: 137.61 (-0.54), GE: 25.15 (+0.26), BOX: 20.18 (+0.01), NKE: 92.04 (+0.04), HON: 104.38 (+0.88), DAL: 44.50 (-0.31), RLYP: 33.98 (+0.60), UNH: 109.44 (-0.40), HAL: 44.19 (+1.42), BAC: 16.61 (-0.06), EEP: 38.84 (-0.50), SLB: 88.38 (+2.42), PEP: 99.13 (-1.14), NFLX: 466.10 (+9.37), SBUX: 91.58 (-0.24), UA: 73.76 (-0.19), PBR: 6.98 (+0.44), WBA: 78.73 (-1.23), IBM: 160.40 (+1.88), STI: 41.57 (+0.01), PTCT: 53.37 (-0.74), LEN.B: 40.12 (-0.13), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP
at The Street - Sat Jan 17, 5:00AM CST
Cramer says he'd buy General Dynamics ahead of earnings and he's a big fan of Honeywell and Pepsico.
GD: 137.61 (-0.54), HON: 104.38 (+0.88), RLYP: 33.98 (+0.60), PTCT: 53.37 (-0.74), PEP: 99.13 (-1.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 16, 7:33PM CST
Cramer will be watching Europe plue earnings from Halliburton, Starbucks and Verizon, among many others.
GD: 137.61 (-0.54), ZIOP: 9.64 (-0.35), AVP: 9.08 (+0.39), HON: 104.38 (+0.88), UNH: 109.44 (-0.40), RLYP: 33.98 (+0.60), DECK: 77.08 (+0.61), HAL: 44.19 (+1.42), CVRR: 20.20 (+0.58), DENN: 10.68 (+0.03), PEP: 99.13 (-1.14), SBUX: 91.58 (-0.24), NFLX: 466.10 (+9.37), IBN: 11.70 (+0.06), IBM: 160.40 (+1.88), PTCT: 53.37 (-0.74), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
FDA sets PDUFA date for Patiromer FOS
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 9:43AM CST
RLYP: 33.98 (+0.60)
Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension
GlobeNewswire - Mon Jan 05, 7:25AM CST
FDA Not Currently Planning to Hold an Advisory Committee Meeting
RLYP: 33.98 (+0.60)
Relypsa added to Biotech Index
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:19AM CST
RLYP: 33.98 (+0.60)
Relypsa to be Added to NASDAQ Biotechnology Index
GlobeNewswire - Wed Dec 17, 7:00AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NASDAQ Biotechnology Index upon market open on Monday, December 22, 2014.
RLYP: 33.98 (+0.60), IBB: 323.46 (+3.04)
Relypsa Announces Stephen D. Harrison, M.A., Ph.D., Joins as Senior Vice President and Chief Scientific Officer
GlobeNewswire - Tue Dec 16, 7:06AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Stephen D. Harrison, M.A., Ph.D., has joined the company as senior vice president and chief scientific officer. Dr. Harrison, a biochemist and molecular biologist, is highly published and has extensive experience leading product-driven research organizations at all stages, from target identification to early clinical development.
RLYP: 33.98 (+0.60)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
FDA accepts Relypsa NDA for hyperkalemia med
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:29AM CST
ZSPH: 46.77 (+3.42), RLYP: 33.98 (+0.60)
Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia
GlobeNewswire - Mon Dec 15, 7:02AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood. Relypsa expects written notification of NDA acceptance along with the Prescription Drug User Fee Act (PDUFA) date (the expected date for completion of FDA review of the NDA), as well as a preliminary indication regarding the need for an Advisory Committee meeting, in the day-74 letter from the FDA in early January 2015.
RLYP: 33.98 (+0.60)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Is Relypsa, Inc. (RLYP) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:47AM CST
Relypsa, Inc. is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
RLYP: 33.98 (+0.60)
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Wed Feb 04, 7:30AM CST
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 2, 2015, the compensation committee of the company's board of directors granted nine new employees an option to purchase an aggregate of 41,400 shares of the company's common stock with a per share exercise price of $32.73, the closing trading price on the grant date. The stock options were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5653(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 33.98 (+0.60)
Relypsa to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 17 Annual BIO CEO & Investor Conference on February 10, 2015 at 9:00 a.m. ET.
RLYP: 33.98 (+0.60)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 46.77 (+3.42), RLYP: 33.98 (+0.60)
Relypsa Announces Helen Torley, M.B. Ch.B., M.R.C.P. Joins Board of Directors
GlobeNewswire - Thu Jan 22, 3:30PM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches.
RLYP: 33.98 (+0.60)
Relypsa: Unglamorous Niche, Exciting Opportunity
Investing Doc - at Seeking Alpha - Tue Jan 20, 12:28PM CST
RLYP: 33.98 (+0.60)
Cramer's Mad Money: Cramer's Game Plan (1/16/15)
SA Editor Michael Hopkins - at Seeking Alpha - Sun Jan 18, 12:06AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 16. After a few big drubbings, stocks caught a break Friday, thanks to a rally in oil and a strong consumer confidence number, data Cramer said is...
GD: 137.61 (-0.54), GE: 25.15 (+0.26), BOX: 20.18 (+0.01), NKE: 92.04 (+0.04), HON: 104.38 (+0.88), DAL: 44.50 (-0.31), RLYP: 33.98 (+0.60), UNH: 109.44 (-0.40), HAL: 44.19 (+1.42), BAC: 16.61 (-0.06), EEP: 38.84 (-0.50), SLB: 88.38 (+2.42), PEP: 99.13 (-1.14), NFLX: 466.10 (+9.37), SBUX: 91.58 (-0.24), UA: 73.76 (-0.19), PBR: 6.98 (+0.44), WBA: 78.73 (-1.23), IBM: 160.40 (+1.88), STI: 41.57 (+0.01), PTCT: 53.37 (-0.74), LEN.B: 40.12 (-0.13), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP
at The Street - Sat Jan 17, 5:00AM CST
Cramer says he'd buy General Dynamics ahead of earnings and he's a big fan of Honeywell and Pepsico.
GD: 137.61 (-0.54), HON: 104.38 (+0.88), RLYP: 33.98 (+0.60), PTCT: 53.37 (-0.74), PEP: 99.13 (-1.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 16, 7:33PM CST
Cramer will be watching Europe plue earnings from Halliburton, Starbucks and Verizon, among many others.
GD: 137.61 (-0.54), ZIOP: 9.64 (-0.35), AVP: 9.08 (+0.39), HON: 104.38 (+0.88), UNH: 109.44 (-0.40), RLYP: 33.98 (+0.60), DECK: 77.08 (+0.61), HAL: 44.19 (+1.42), CVRR: 20.20 (+0.58), DENN: 10.68 (+0.03), PEP: 99.13 (-1.14), SBUX: 91.58 (-0.24), NFLX: 466.10 (+9.37), IBN: 11.70 (+0.06), IBM: 160.40 (+1.88), PTCT: 53.37 (-0.74), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
FDA sets PDUFA date for Patiromer FOS
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 9:43AM CST
RLYP: 33.98 (+0.60)
Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension
GlobeNewswire - Mon Jan 05, 7:25AM CST
FDA Not Currently Planning to Hold an Advisory Committee Meeting
RLYP: 33.98 (+0.60)
Relypsa added to Biotech Index
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:19AM CST
RLYP: 33.98 (+0.60)
Relypsa to be Added to NASDAQ Biotechnology Index
GlobeNewswire - Wed Dec 17, 7:00AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NASDAQ Biotechnology Index upon market open on Monday, December 22, 2014.
RLYP: 33.98 (+0.60), IBB: 323.46 (+3.04)
Relypsa Announces Stephen D. Harrison, M.A., Ph.D., Joins as Senior Vice President and Chief Scientific Officer
GlobeNewswire - Tue Dec 16, 7:06AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Stephen D. Harrison, M.A., Ph.D., has joined the company as senior vice president and chief scientific officer. Dr. Harrison, a biochemist and molecular biologist, is highly published and has extensive experience leading product-driven research organizations at all stages, from target identification to early clinical development.
RLYP: 33.98 (+0.60)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
FDA accepts Relypsa NDA for hyperkalemia med
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:29AM CST
ZSPH: 46.77 (+3.42), RLYP: 33.98 (+0.60)
Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia
GlobeNewswire - Mon Dec 15, 7:02AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood. Relypsa expects written notification of NDA acceptance along with the Prescription Drug User Fee Act (PDUFA) date (the expected date for completion of FDA review of the NDA), as well as a preliminary indication regarding the need for an Advisory Committee meeting, in the day-74 letter from the FDA in early January 2015.
RLYP: 33.98 (+0.60)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Is Relypsa, Inc. (RLYP) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:47AM CST
Relypsa, Inc. is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
RLYP: 33.98 (+0.60)
